Results 11 to 20 of about 22,540 (195)

Anakinra Therapy for Non-cancer Inflammatory Diseases [PDF]

Frontiers in Pharmacology, 2018
Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-
Giulio Cavalli, Giulio Cavalli, Charles A. Dinarello, Charles A. Dinarello   +3 more
doaj   +6 more sources

A randomised trial evaluating anakinra in early active rheumatoid arthritis. [PDF]

, 2016
OBJECTIVES:The effectiveness of anakinra (interleukin-1 receptor antagonist) in early rheumatoid arthritis (RA) is unknown. We evaluated the efficacy of anakinra (combined with methotrexate) in a randomised clinical trial of early active RA patients ...
Ibrahim, Fowzia, Kowalczyk, Anna, Plant, Michael, White-Alao, Beverley, Scott, David L, Walker, David, Scott, Ian C, Hassell, Andrew, Simpson, Gemma, Richards, Selwyn   +9 more
core   +17 more sources

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports

International Journal of General Medicine, 2011
Mahmud Mahamid1,3, Kalman Paz3, Rifaat Safadi1,21Liver Unit, Holy Family Hospital, Nazareth, Israel; 2Hadassah Medical Center, 3Shaare Zedek Medical Center, Jerusalem, IsraelAbstract: Elevation of liver enzymes in patients with rheumatoid arthritis ...
Mahamid M, Paz K, Safadi R
doaj   +1 more source

Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety

Drug Design, Development and Therapy, 2014
Dongsheng Hong,1 Zhihai Yang,1 Shuyin Han,1 Xingguang Liang,1 Kuifen Ma,1 Xingguo Zhang1,2 1Department of Pharmacy, the First Affiliated Hospital of College of Medicine, Zhejiang University, 2College of Pharmaceutical Science, Zhejiang Chinese Medical ...
Hong D, Yang Z, Han SY, Liang X, Ma K, Zhang X   +5 more
doaj   +1 more source

Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project

Biologics: Targets & Therapy, 2009
Kylie Thaler1, Divya V Chandiramani2, Richard A Hansen2, Gerald Gartlehner11Department for Evidence-based Medicine and Clinical Epidemiology, Danube University Krems, Krems, Austria; 2UNC Eshelman School of Pharmacy, University of North Carolina
Kylie Thaler, Divya V Chandiramani, Richard A Hansen, et al   +3 more
doaj   +1 more source

Model-Informed Dose Optimization of Anakinra in Preterm Neonates Implications for Safe and Effective Dosing. [PDF]

Clin Pharmacol Ther
Anakinra, an interleukin‐1 receptor antagonist, shows promise for reducing inflammatory complications of premature birth. However, the pharmacokinetics (PK) of anakinra in neonates has not been characterized, limiting evidence‐based dosing. This study aimed to develop a population PK model for anakinra to guide dosing in preterm neonates.
Li J, Metz DK, Green E, Toldi G, Galinsky R, Clark M, Atkinson R, Rudloff I, Owen JC, DiSimone SK, Forster SC, Cho SX, Majid A, Polglase GR, Favilla M, Pharande P, Malhotra A, Roberts CT, Stansfield SH, Sehgal A, Tan K, Gunn AJ, Berger PJ, Veldman A, Hunt RW, Nold-Petry CA, Nold MF, Kirkpatrick CMJ.   +27 more
europepmc   +2 more sources

Interleukin-1α Mediates Pancreatic Fibroblast Activation, Regulates Immune Cell Recruitment and Fibrosis in Acute and Chronic Pancreatitis. [PDF]

Adv Sci (Weinh)
During pancreatitis, IL‐1α is released from necrotic acinar cells. In response to IL‐1α, pancreatic fibroblasts release chemokines and cytokines that regulate the recruitment of immune cells to the damaged organ. Furthermore, IL‐1α primes fibroblasts, resulting in increased tissue fibrosis during chronic pancreatitis.
Mazloum H, Buchholz S, Schifter H, Ameling S, Steil L, Becker BL, Hammer E, Homuth G, Völker U, Bröker BM, Zierke L, Weiss FU, Glaubitz J, Sendler M.   +13 more
europepmc   +2 more sources

Anakinra for recalcitrant pyoderma gangrenosum [PDF]

, 2021
Pyoderma gangrenosum (PG) is an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, painful ulcers. Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist that blocks the activity of IL-1α and IL-1β by competitively ...
Hollywood, Aoife, Paul, Lindsay, O\u27Connor, Cathal, O'Connell, Michael, Gallagher, Catriona, O'Connor, Cathal, O\u27Connell, Michael   +6 more
core   +1 more source

Continuous IV infusion of anakinra [PDF]

, 2023
Objective: A review of the use of continuous IV infusion of anakinra; a description of the protocol for continuous IV infusion of anakinra in the treatment of cytokine storm developed over the past 4 years at a tertiary level academic medical center in ...
Marcela V. Kuijpers, Jason J. Sloan, Brittney N. Saunders, Elie Gertner   +3 more
core   +1 more source

Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.

PLoS ONE, 2023
BackgroundIn patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death.
Francesco Vladimiro Segala, Emanuele Rando, Federica Salvati, Marcantonio Negri, Francesca Catania, Flavia Sanmartin, Rita Murri, Evangelos J Giamarellos-Bourboulis, Massimo Fantoni   +8 more
doaj   +1 more source